LON:SLN - Silence Therapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 324 +20.00 (+6.58 %) (As of 01/17/2020 08:22 AM ET) Add Compare Today's Range 302.24Now: GBX 324▼ 33050-Day Range 304MA: GBX 430.72▼ 60552-Week Range 40Now: GBX 324▼ 613.80Volume62,252 shsAverage Volume13,380 shsMarket Capitalization£253.92 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. Read More… Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SLN Previous Symbol CUSIPN/A CIKN/A Webhttp://www.silence-therapeutics.com/ Phone+44-20-34576900Debt Debt-to-Equity RatioN/A Current Ratio7.26 Quick Ratio6.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 23.20 per share Price / Cash Flow13.97 Book ValueGBX 38.10 per share Price / Book8.50Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares78,370,304Market Cap£253.92 million Next Earnings DateN/A OptionableNot Optionable Receive SLN News and Ratings via Email Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. LSE:SLN Rates by TradingView Silence Therapeutics (LON:SLN) Frequently Asked Questions What is Silence Therapeutics' stock symbol? Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN." How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (LON:SLN) released its quarterly earnings data on Tuesday, September, 11th. The company reported ($12.40) earnings per share (EPS) for the quarter. View Silence Therapeutics' Earnings History. What is the consensus analysts' recommendation for Silence Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silence Therapeutics. Has Silence Therapeutics been receiving favorable news coverage? News coverage about SLN stock has trended positive on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Silence Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Silence Therapeutics. Who are some of Silence Therapeutics' key competitors? Some companies that are related to Silence Therapeutics include Immutep (IMM), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Oxford BioMedica (OXB), Bellus Health (BLU), Starpharma (SPL), Pfenex (PFNX), TELIX Pharmaceutical (TLX), Biotest (BIO), Pfenex (PFNX), Cel-Sci (CVM), Neptune Wellness Solutions (NEPT), ProMetic Life Sciences (PLI), Theratechnologies (TH) and Rafael (RFL). What other stocks do shareholders of Silence Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include QuickLogic (QUIK), Arch Therapeutics (ARTH), Clarkson (CKN), Charter Court Financial Services Grp (CCFS), Close Brothers Group (CBG), Bodycote (BOY), Bank of Ireland Group (BIRG), British American Tobacco Plc Ads (BATS), AstraZeneca (AZN) and Avast (AVST). Who are Silence Therapeutics' key executives? Silence Therapeutics' management team includes the folowing people: Dr. David Horn Solomon, CEO & Director (Age 59)Dr. Rob Quinn, Chief Financial OfficerDr. Mark Cameron, Head of ChemistryMr. Richard Jenkins, Head of Clinical Devel. How do I buy shares of Silence Therapeutics? Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Silence Therapeutics' stock price today? One share of SLN stock can currently be purchased for approximately GBX 324. How big of a company is Silence Therapeutics? Silence Therapeutics has a market capitalization of £253.92 million. View Additional Information About Silence Therapeutics. What is Silence Therapeutics' official website? The official website for Silence Therapeutics is http://www.silence-therapeutics.com/. How can I contact Silence Therapeutics? Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900. MarketBeat Community Rating for Silence Therapeutics (LON SLN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 169 (Vote Underperform)Total Votes: 351MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2020 by MarketBeat.com StaffFeatured Article: Are sell-side analysts objective?
